
Revolutionary Breakthrough: Kadcyla Outshines Herceptin in Prolonging Life for Breast Cancer Patients
Kadcyla (ado-trastuzumab emtansine, T-DM1) shows significant superiority over Herceptin in treating HER2-positive early breast cancer, with groundbreaking results from the KATHERINE trial. At an 8.4-year median follow-up, Kadcyla increased invasive disease-free survival to 80.8% versus Herceptin’s 67.1% and achieved a seven-year overall